Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
Those bargain vials and custom doses are uncharted waters with almost zero formal data
But a recent mouse study showed that semaglutide doesnt really target these preproglucagon neurons and instead acts more on the peripheral systems.[ref] GLP-1 receptors are also found on pancreatic beta cells, triggering insulin release
No prescriptions, no doctor visits, no pharmacy lines
You can see why in my full review of it here
The complaints have led to injunctions and court orders blocking unapproved sales